TY  - JOUR

T1  - Cost-effectiveness of lapatinib plus capecitabine (LAP plus C) versus capecitabine alone (C-only) or trastuzumab plus capecitabine (TZ plus C) in women with HER2-positive metastatic breast cancer (MBC) who have received prior therapy with trastuzumab (TZ) from the UK National Health Service (NHS) perspective

JO  - JOURNAL OF CLINICAL ONCOLOGY

PY  - 2010/05/20

AU  - Sofrygin O

AU  - Delea TE

AU  - Tappenden P

AU  - Karnon J

AU  - Browning D

AU  - Amonkar M

AU  - Lykopoulos K

AU  - Cameron DA

ED  - 

DO  - DOI: 10.1200/jco.2010.28.15_suppl.6037

VL  - 28

IS  - 15

Y2  - 2025/04/05

ER  -